Article

Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma.

Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Cancer Science (impact factor: 3.33). 12/2008; 100(2):233-7. DOI:10.1111/j.1349-7006.2008.01035.x pp.233-7
Source: PubMed

ABSTRACT Diffuse large B-cell lymphoma (DLBCL) has heterogeneous clinical, histological, and molecular features. We evaluated the clinical characteristics and prognoses of patients with DLBCL carrying 8q24 translocations. A total of 1864 consecutive patients with non-Hodgkin's lymphoma were treated in the Adult Lymphoma Treatment Study Group from 1998 to 2005. Of the 252 patients with DLBCL with abnormal karyotypes, 28 patients with DLBCL with the 8q24 translocation were identified. There were 14 men and 14 women, with a median age of 61 years. The 8q24 translocation was observed significantly more frequently among patients with poor performance status, among patients with high lactate dehydrogenase level, and among patients with bone marrow involvement. The 5-year overall survival was 43.9% among the patients with 8q24 translocation, and 67% among the patients with other chromosomal abnormalities. The 8q24 translocation group showed significantly poorer prognosis than the group with other translocations. In addition, patients with t(14;18) and 8q24 translocation showed significantly poorer prognosis than those with 8q24 translocation alone. It will be necessary to study whether more aggressive chemotherapy or rituximab combination chemotherapy is effective in 8q24 translocation cases.

0 0
 · 
0 Bookmarks
 · 
25 Views
  • Source
    Article: Dominant genetic aberrations and coexistent EBV infection in HIV-related oral plasmablastic lymphomas.
    Sonja C Boy, Marlene B van Heerden, Chantal Babb, Willie F van Heerden, Pascale Willem
    [show abstract] [hide abstract]
    ABSTRACT: We present common cytogenetic features in the largest cohort of plasmablastic lymphoma (PBL) of the oral cavity published to date. This cohort included 45 patients, 32 of whom had a known HIV status, of which 31 were HIV positive. Ninety eight per cent of all PBL cases were known to be EBV positive. In line with previous studies, we found that rearrangements of the MYC gene was the most common genetic abnormality seen in 60% of cases with the immunoglobulin heavy chain (IGH) locus as a partner in 51% of cases. Additional complex genetic aberrations were frequent, in particular, an increased copy number of the CCND1 gene was seen in 41% of cases with true amplification of CCND1 in 15% of cases. Aneuploidy was also observed for the BCL6 gene in 28% of cases. Interestingly, rearrangements of both IGH genes were detected in 16% of cases with t(14;18) and t(11;14) respectively involved in conjunction with a t(8;14) in two cases. These bi-allelic IGH rearrangements have not been described before in oral PBL. Our results reinforce the notion that EBV infection and MYC rearrangements are important events in the pathogenesis of oral PBL. The genetic diversity and complexity observed in these cases, underlines the importance to genetically characterise PBL patients at presentation as this may inform the choice of more effective treatment modalities.
    Oral Oncology 07/2011; 47(9):883-7. · 2.86 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

1864 consecutive patients
 
28 patients
 
abnormal karyotypes
 
Adult Lymphoma Treatment Study Group
 
aggressive chemotherapy
 
bone marrow involvement
 
chromosomal abnormalities
 
clinical characteristics
 
Diffuse large B-cell lymphoma
 
DLBCL
 
histological
 
lactate dehydrogenase level
 
median age
 
molecular features
 
non-Hodgkin's lymphoma
 
patients
 
poor performance status
 
poorer prognosis
 
prognoses
 
rituximab combination chemotherapy
 

Nozomi Nitsu